Excessive Daytime Sleepiness (EDS) Market to Reach USD 9.12 Billion by 2034

Pune, India - December 2025 - The global Excessive Daytime Sleepiness (EDS) Market, valued at USD 5.23 billion in 2024, is projected to reach USD 9.12 billion by 2034, growing at a 5.7% CAGR (2025-2034), according to Exactitude Consultancy. Rising prevalence of sleep disorders, growing use of wake-promoting medications, and improved diagnostic capabilities are driving strong market momentum.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71903

Market Summary
The EDS Market is expanding rapidly as excessive daytime sleepiness-defined as an inability to stay awake and alert during normal daytime hours-becomes increasingly recognized across sleep medicine and neurology. EDS is commonly associated with narcolepsy, obstructive sleep apnea (OSA), idiopathic hypersomnia, shift-work disorder, Parkinson's disease, depression, and several neurological or metabolic disorders.

Treatment strategies are evolving from traditional stimulants to modern wake-promoting agents such as modafinil, armodafinil, solriamfetol, and pitolisant, which offer improved safety, reduced abuse potential, and strong efficacy. Increasing adoption of positive airway pressure (PAP) therapy, behavioral sleep interventions, and sleep hygiene programs also supports the market.

Diagnostics such as polysomnography (PSG), multiple sleep latency testing (MSLT), actigraphy, and home-based sleep monitors are enabling earlier and more accurate identification of underlying causes.
North America leads due to high screening rates and widespread use of EDS medications, while Asia-Pacific is the fastest-growing region, driven by rising sleep disorder awareness and lifestyle-related fatigue.

Key Takeaways
• 2024 Market Size: USD 5.23 Billion
• 2034 Forecast: USD 9.12 Billion
• CAGR: 5.7% (2025-2034)**
• Wake-promoting agents continue to dominate the treatment landscape
• OSA and narcolepsy remain the most common underlying causes
• Growing adoption of home sleep testing boosting diagnosis rates

Market Drivers
• Rising prevalence of sleep disorders globally
• Increased use of wake-promoting medications (solriamfetol, pitolisant)
• Growth in polysomnography and home sleep apnea testing
• Greater awareness of fatigue-related workplace and driving accidents
• Integration of digital health tools & wearables for sleep monitoring

Segmentation Snapshot
By Drug Class
• Wake-Promoting Agents
o Modafinil
o Armodafinil
o Solriamfetol
o Pitolisant
• Stimulants (Methylphenidate, Amphetamines)
• Antidepressants (For Comorbid Conditions)
• Emerging Orexin-Modulating Therapies

By Underlying Disorder
• Obstructive Sleep Apnea (Largest Segment)
• Narcolepsy
• Idiopathic Hypersomnia
• Shift-Work Sleep Disorder
• Psychiatric & Neurological Disorders
• Medication-Induced Sleepiness

By Diagnosis
• Polysomnography
• Multiple Sleep Latency Test (MSLT)
• Actigraphy
• Home Sleep Testing
• Clinical Evaluation & Sleep Questionnaires

By End User
• Hospitals
• Sleep Centers & Clinics
• Neurology Clinics
• Homecare Settings
• Digital Sleep Platforms

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71903/excessive-daytime-sleepiness-eds-market

Recent Developments
• Solriamfetol and pitolisant gaining expanded indications for EDS across various sleep disorders.
• Increased use of home-based sleep apnea testing to reduce diagnostic delays.
• Development of next-generation orexin agonists showing strong potential for narcolepsy-related EDS.
• Wearable sleep-tracking devices integrating AI analytics into fatigue prediction.

Expert Quote - Irfan Tamboli, Business Development Executive
"Excessive daytime sleepiness has emerged as a major public health concern impacting productivity, safety, and quality of life. Advancements in wake-promoting therapies and home sleep diagnostics are transforming patient outcomes worldwide."

Conclusion
The Excessive Daytime Sleepiness Market will continue expanding through 2034 as awareness of sleep health rises, diagnostic tools proliferate, and next-generation wake-promoting agents gain global adoption. Companies leading in sleep diagnostics, neurology therapeutics, and digital fatigue-management platforms are positioned for significant growth.

This report is also available in the following languages : Japanese (日中の過度の眠気(EDS)市場), Korean (과도한 주간 졸음증(EDS) 시장), Chinese (白天过度嗜睡症(EDS)市场), French (Marché de la somnolence diurne excessive (SDE)), German (Markt für übermäßige Tagesschläfrigkeit (EDS)), and Italian (Mercato della sonnolenza diurna eccessiva (EDS)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71903

Related Reports
Narcolepsy Market
https://exactitudeconsultancy.com/reports/51994/narcolepsy-market

Portable Sleep Diagnostic System Market
https://exactitudeconsultancy.com/reports/59127/global-portable-sleep-diagnostic-system-market

Modafinil Market
https://exactitudeconsultancy.com/reports/66409/modafinil-market

Polysomnography Devices Market
https://exactitudeconsultancy.com/reports/50191/polysomnography-devices-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.